Emerging Breast Cancer Therapies and Closing Thoughts

A leading oncologist explores promising new breast cancer therapies in the drug development pipeline and advises healthcare providers on strategies to remain informed about the most current treatment guidelines and recommendations.

EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer

EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024

EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib

EP: 6.Exploring Results from CAPItello-291 Trial

EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer

EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook

Now Viewing

EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts

1. What drug developments are targeting unmet needs in breast cancer treatment? What drugs are currently in the pipeline that you are excited about?
2. How can healthcare providers stay updated with the latest breast cancer treatment guidelines?

Related Videos

Related Content

Advertisement

November 20th 2024

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

Brooke McCormick

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 19th 2024

Influenza Antiviral Treatment Underutilized Among Eligible Children, Adolescents

Brooke McCormick

Influenza antiviral treatment remains underutilized among eligible children and adolescents, particularly in outpatient settings, despite CDC recommendations.

November 19th 2024

New PsA Data Highlight Long-Term Benefits of Bimekizumab

Maggie L. Shaw

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).

Related Content

Advertisement

November 20th 2024

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

Brooke McCormick

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 19th 2024

Influenza Antiviral Treatment Underutilized Among Eligible Children, Adolescents

Brooke McCormick

Influenza antiviral treatment remains underutilized among eligible children and adolescents, particularly in outpatient settings, despite CDC recommendations.

November 19th 2024

New PsA Data Highlight Long-Term Benefits of Bimekizumab

Maggie L. Shaw

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).